A pooled analysis including KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 study endorses the use of pembrolizumab for treatment of advanced melanoma independent of BRAF V600 mutation status or previous treatment with BRAF inhibitor with or without MEK inhibitor. The gene discussed is MAP2K7; the disease is melanoma.